OFF-X is the first alerting service that allows drug R&D professionals to be promptly informed about the target modulating effects of small molecules and biologics leading to preclinical toxicity and clinical adverse events.
It is a comprehensive information system classified by drug target (molecular mechanism of action) and adverse events. It covers both known and new safety issues associated to target classes. OFF-X also enables users to anticipate new target class liabilities based on mounting evidence for individual drugs sharing a particular mechanism of action.
OFF-X provides daily alerts of safety issues reported in diverse sources including biomedical literature, congresses, company and regulatory agency communications. Users can search the database by target to obtain comprehensive information on its related safety issues or search by adverse event to identify the targets linked with it.
By helping users anticipate the potential safety issues of an investigational drug based on its pharmacological profile, OFF-X aims to de-risk projects and speed up drug discovery and development, reducing time, costs and attrition rates.
Multiple annual subscription options are available including online access, API and data feed.
OFF-X is developed by BioInfoGate, a forward thinking, private company working to solve unmet medical needs. Our innovative data analytics products support the discovery and development of better and safer drugs. We are committed to building industry leading solutions and also identifying and investing in emerging projects that align with our core business in life sciences.